ライフサイエンスコーパス: interferon alfa

1 nonconventional therapeutic approaches (eg, interferon-alfa).

2 o received sunitinib than in those receiving interferon alfa.

3 rance and a longer half-life than unmodified interferon alfa.

4 olidation chemotherapy, and maintenance with interferon alfa.

5 e; seven patients received TMZ with low-dose interferon alfa.

6 -line metastatic RCC population treated with interferon alfa.

7 trategy for minimizing depression induced by interferon alfa.

8 ome patients in each subgroup can respond to interferon alfa.

9 nd in those with a history of treatment with interferon alfa.

10 rvival and response to adjuvant therapy with interferon alfa.

11 d February 2010 for CIN lesions used topical interferon alfa 1 million IU/ml drops 4 times daily and

12 patitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV)

13 sed double-blind placebo-controlled trial of interferon alfa-2a (10 million units/m2, daily for 7 day

14 trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for

15 day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plu

16 Interferon alfa-2a (IFN-alpha2a) was administered at 9 m

17 etyl-L-aspartic acid (PALA), and recombinant interferon alfa-2a (IFNalpha-2a) in a sequential order t

18 Pegylated (40 kd) interferon alfa-2a (IFNalpha2a) (PEGASYS, Hoffman-La Roc

19 rapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFNalpha2a) is superior to IFNalpha2

20 We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with e

21 ovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patients with chronic HBV

22 ompared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either r

23 of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-

24 days, then 750 mg/m2 weekly, and recombinant interferon alfa-2a 9 million units subcutaneously three

25 r 90 mug/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen.

26 Pegylated interferon alfa-2a administered once weekly is more effe

27 once weekly is more effective than standard interferon alfa-2a administered three times weekly.

28 ined virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepati

29 llocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with int

30 l or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have

31 ere reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving comb

32 2 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment

33 , >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

34 Therapy for HCL includes splenectomy, interferon alfa-2a and alfa-2b, pentostatin, and cladrib

35 jection (CR) in patients receiving pegylated interferon alfa-2a and ribavirin (PEG) to treat recurren

36 8), telaprevir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 da

37 zed 1:1:2:2 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combina

38 th TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNalpha-2a and RBV

39 (Virahep-C), 260 men treated with pegylated interferon alfa-2a and ribavirin completed self-administ

40 All patients received pegylated interferon alfa-2a and ribavirin therapy.

41 ng recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxi

42 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematological and

43 The doses of interferon alfa-2a given in this regimen did not improve

44 owledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants

45 Peg-interferon alfa-2a immunotherapy resulted in control of

46 afety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and hepa

47 Pegylated interferon alfa-2a induced haematological (66 [80%] of 8

48 Pegylated interferon alfa-2a is an immunomodulatory agent used to

49 At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was ob

50 REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks, then mono

51 eks, then monotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

52 plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 per

53 a lower likelihood of SVR than was pegylated interferon alfa-2a plus ribavirin (absolute difference,

54 us either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of c

55 was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-

56 ron alfa-2a plus placebo, and 7 percent with interferon alfa-2a plus ribavirin.

57 Interferon alfa-2a resembles other recombinant alpha int

58 ERPRETATION: Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well tolerated, and

59 cts were assigned to receive 6 million IU of interferon alfa-2a three times weekly for 12 weeks follo

60 .8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for th

61 The initial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously once per w

62 After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the

63 uvant chemoprevention with retinoic acid and interferon alfa-2A was offered.

64 Pegylated interferon alfa-2a was well tolerated and exhibited stat

65 V infection received 180 microg of pegylated interferon alfa-2a weekly for 12 weeks.

66 d) provides improved sustained response over interferon alfa-2a, but its effect on HRQL is unknown.

67 astatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil prod

68 on alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.

69 Seven were treated with corticosteroids, interferon alfa-2a, or both.

70 1 IU/mL before the introduction of pegylated interferon alfa-2a.

71 compared peginterferon alfa-2a (40 kd) with interferon alfa-2a.

72 patients receiving combination treatment or interferon alfa-2a.

73 Use of interferon alfa-2a/2b and ribavirin, 1000 to 1200 mg/d,

74 imeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.

75 of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the comb

76 -label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mug/wk, or albIF

77 nt with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), p

78 odeficiency virus were randomized to receive interferon alfa-2b (3 million units 3 times a week) plus

79 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three

80 ng either consensus interferon (9 microg) or interferon alfa-2b (3 million units) given three times w

81 yotherapy with adjuvant topical or injection interferon alfa-2b (38% vs 15%).

82 r alone or concurrent with interleukin-2 and interferon alfa-2b (BCT).

83 High-dose interferon alfa-2b (HDI) has emerged as a potentially ef

84 High-dose interferon alfa-2b (HDI) was administered concurrently,

85 Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma

86 cted with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times wee

87 for hepatitis C, we assessed the efficacy of interferon alfa-2b (IFN) in preventing recurrent hepatit

88 value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2

89 As second-line therapy, he received interferon alfa-2b (IFN--2b) 2.7 MU daily, which he tole

90 C melanoma were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenou

91 ession-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide am

92 Interleukin-12 (IL-12) and interferon alfa-2b (IFN-alpha-2b) are pleiotropic cytoki

93 tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-li

94 estigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose oste

95 d active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved u

96 reliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanc

97 High-dose interferon alfa-2b (IFNalpha2b) is the only established

98 Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk mel

99 Adjuvant pegylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for t

100 nts treated with variable-duration pegylated interferon alfa-2b (PEG-IFN-alpha2b) and RBV.

101 riple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which

102 I trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched wit

103 Recombinant interferon alfa-2b (rIFNalpha2b) is a standard therapy f

104 Treatment consisted of interferon alfa-2b 10 x 10(6) U subcutaneously three tim

105 sis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly syn

106 mes a week) plus ribavirin (1,000 mg/day) or interferon alfa-2b alone for 48 weeks with 24 weeks of p

107 oic acid may offer a superior alternative to interferon alfa-2b alone in treating CIN.

108 chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribaviri

109 ed in 3 published clinical trials evaluating interferon alfa-2b alone or with ribavirin either as ini

110 pared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of

111 umor-free period compared with studies using interferon alfa-2b alone.

112 bazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2.

113 l of 1,744 patients with HCV received either interferon alfa-2b and placebo or combination interferon

114 We believe that combination treatment of interferon alfa-2b and retinoic acid may offer a superio

115 white nonresponders (NR) to a combination of interferon alfa-2b and ribavirin (IFN + R).

116 rly virologic response [EVR]) with pegylated interferon alfa-2b and ribavirin (PEG/R) in identifying

117 nterferon alfa-2b and placebo or combination interferon alfa-2b and ribavirin for 24 or 48 weeks.

118 alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatme

119 he efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chroni

120 For chronic hepatitis C, the combination of interferon alfa-2b and ribavirin is the treatment of cho

121 Multiple-dose interferon alfa-2b and ribavirin peak and trough concent

122 ated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple rec

123 NA positive after 6 months of treatment with interferon alfa-2b but had a histological response.

124 (on days 5 to 8, 17 to 20, and 26 to 29) and interferon alfa-2b by subcutaneous injection (on days 5

125 atitis B, treatment with a 4-month course of interferon alfa-2b can achieve hepatitis B e antigen ser

126 t recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and

127 ssigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to

128 either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW)

129 nts receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of

130 day) or RBV (800-1400 mg/day) with pegylated interferon alfa-2b for 48 weeks.

131 Patients received interferon alfa-2b for a minimum of 4 weeks, followed by

132 ompared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensa

133 he efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C.

134 Treatment with interferon alfa-2b has been limited by its cost and low

135 therapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved

136 Adjuvant therapy with interferon alfa-2b holds promise for patients with metas

137 In conclusion, interferon alfa-2b in combination with ribavirin is effe

138 all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C.

139 ize that topical all-trans retinoic acid and interferon alfa-2b may act synergistically.

140 conditions were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK

141 radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b ther

142 on of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 per

143 Children receiving interferon alfa-2b plus ribavirin 15 mg/kg/d in the phas

144 a-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significa

145 stained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-

146 Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a

147 ety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alf

148 terferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin.

149 hout adjuvant oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.

150 mized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph nod

151 Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard a

152 herapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone.

153 itis C virus (HCV) were treated with 5 MU of interferon alfa-2b three times weekly for 6 months.

154 2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin fo

155 rogressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent

156 ery from melphalan, patients were to receive interferon alfa-2b until relapse.

157 ation treatment of topical retinoic acid and interferon alfa-2b was effective in treating lesions wit

158 y for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard dos

159 1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile.

160 azine, decrescendo interleukin-2 (IL-2), and interferon alfa-2b with granulocyte-macrophage colony-st

161 acarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon alfa-2b).

162 erapy, oral cimetidine, topical or injection interferon alfa-2b, and photodynamic therapy.

163 e, vinblastine, cisplatin, decrescendo IL-2, interferon alfa-2b, and tamoxifen was repeated at 21-day

164 evoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing

165 en subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and

166 polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C

167 er inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustai

168 Interferon alfa-2b-treated patients also had significant

169 apy consisting of CVD plus interleukin-2 and interferon alfa-2b.

170 atment and after follow-up, as compared with interferon alfa-2b.

171 only complicates treatment with the cytokine interferon alfa-2b.

172 who are candidates for adjuvant therapy with interferon alfa-2b.

173 nfection were treated with standard doses of interferon alfa-2b.

174 Monotherapy with standard or pegylated interferon alfa-2b; combination therapy with standard or

175 mination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and

176 Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overa

177 toxicity associated with adjuvant high-dose interferon-alfa-2b therapy (HDI) for high-risk melanoma

178 pensated cirrhosis, combination therapy with interferon alfa (3 million units [MU] 3 times a week) an

179 th a higher objective response rate than was interferon alfa (31% vs. 6%, P<0.001).

180 -2 total dose of 36 MU/m2 during 4 days, and interferon alfa 5 MU/m2 on days 1 to 5.

181 ith chronic delta hepatitis was treated with interferon alfa, 5 million units daily for 12 years.

182 Interleukin 2 (13.5 million IU/m2/d) and interferon alfa (6 MU/m2/d) were administered on days 4

183 The use of high-dose interferon alfa adjuvant therapy in pediatric patients h

184 lfa and cytarabine appears to be superior to interferon alfa alone.

185 udies have reported a lower response rate to interferon alfa among black patients with chronic hepati

186 t was begun 2 weeks before the initiation of interferon alfa and continued for the first 12 weeks of

187 The combination of interferon alfa and cytarabine appears to be superior to

188 The standard of care has been subcutaneous interferon alfa and oral ribavirin for 24-72 weeks.

189 atients were treated with the combination of interferon alfa and ribavirin for 24 weeks; those who fa

190 Because pegylated interferon alfa and ribavirin remain a key part of the t

191 Interferon alfa and ribavirin therapy lead to sustained

192 rsons, 22 white persons) undergoing combined interferon alfa and ribavirin therapy.

193 Successful eradication of HCV with interferon alfa and ribavirin was shown to improve some

194 hepatitis C treated with the combination of interferon alfa and ribavirin were analyzed.

195 Telaprevir, combined with pegylated interferon alfa and ribavirin, is an efficacious approac

196 was 5% to 10% higher with standard doses of interferon alfa and ribavirin.

197 of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with tha

198 ment was categorized as cytokine (containing interferon alfa and/or interleukin-2) in 396 patients (5

199 e therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of cho

200 virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort

201 rus (HCV) in patients treated with pegylated interferon-alfa and ribavirin.

202 locyte macrophage colony-stimulating factor, interferon-alfa, and recombinant interleukin-2 (rIL-2).

203 tine, dacarbazine, interleukin-2 (IL-2), and interferon alfa as part of a clinical trial, he develope

204 s, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU given subcutaneously

205 Interferon alfa-based regimens used to treat recurrent h

206 infection and respond poorly to therapy with interferon alfa-based regimens, but they have been under

207 pression necessitated the discontinuation of interferon alfa before 12 weeks in 1 of the 20 patients

208 Treatment of hepatitis C with interferon-alfa can lead to sustained clearance of HCV,

209 ion to maintenance therapy with rituximab or interferon alfa, each given until progression.

210 the sunitinib group (11 months) than in the interferon alfa group (5 months), corresponding to a haz

211 ter quality of life than did patients in the interferon alfa group (P<0.001).

212 Stem-cell transplantation and the use of interferon alfa had already offered the possibility of c

213 onic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of o

214 in patients with CML in whom treatment with interferon alfa had failed.

215 in the chronic phase in whom treatment with interferon alfa had failed.

216 The efficacy of interferon alfa has been established in treating advance

217 Interferon alfa has improved the median durations of chr

218 n remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death,

219 RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10)

220 To assess the benefits of adjuvant high-dose interferon alfa (HDI) treatment for patients with high-r

221 Treatment of HDV is with pegylated interferon alfa; however, response rates are poor.

222 in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic he

223 Interferon alfa (IFN) is a historic standard first-line

224 file for the combination of temsirolimus and interferon alfa (IFN) were determined in patients with a

225 Since interferon alfa (IFN-A) became an established treatment

226 ents with hepatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-sti

227 ents with hepatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-sti

228 Although interferon alfa (IFN-alpha) and ribavirin are widely use

229 This study compared the efficacy of interferon alfa (IFN-alpha) and ribavirin monotherapies

230 ated statistically significant efficacy over interferon alfa (IFN-alpha) as first-line therapy in pat

231 f adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-alpha) for preventing tumor recurre

232 s the anti-hepatitis C virus (HCV) effect of interferon alfa (IFN-alpha) in patients with HCV infecti

233 l demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival

234 Interferon alfa (IFN-alpha) induces complete cytogenetic

235 Interferon alfa (IFN-alpha) is an approved therapeutic a

236 Interferon alfa (IFN-alpha) is currently the only well-e

237 Interferon alfa (IFN-alpha) is the historic standard ini

238 egion in patients receiving RBV, placebo, or interferon alfa (IFN-alpha) monotherapy.

239 Interferon alfa (IFN-alpha) production in response to in

240 Interferon alfa (IFN-alpha) therapy remains a mainstay o

241 L activity may impact subsequent response to interferon alfa (IFN-alpha) therapy.

242 anulocyte colony-stimulating factor (G-CSF), interferon alfa (IFN-alpha), macrophage inflammatory pro

243 Interferon alfa (IFN-alpha)-based treatment is the only

244 ions have been implicated in spontaneous and interferon alfa (IFN-alpha)-related hepatitis B e antige

245 bleomycin (CHOP-Bleo); CHOP-Bleo followed by interferon alfa (IFN-alpha); a rotation of three regimen

246 The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML)

247 Many of the toxicities associated with interferon-alfa (IFN-alpha) seem to be the result of end

248 ) who had experienced treatment failure with interferon alfa (IFNalpha) therapy.

249 f chemotherapy, and act synergistically with interferon alfa (IFNalpha) to inhibit tumor cell growth

250 The purpose of this study was to test interferon alfa (IFNalpha), 13-cis-retinoic acid (13cRA)

251 y antiviral treatment, 38% were treated with interferon alfa (IFNalpha)-based therapies, and 33% rece

252 n with survival and response to therapy with interferon alfa in 214 patients from two independent, pr

253 ell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted.

254 pression patterns, survival, and response to interferon alfa in both men and women with the disease.

255 In conclusion, long-term therapy with interferon alfa in high doses led to resolution of chron

256 The use of interferon alfa in the pediatric population was also rev

257 Interferon alfa induced complete hematologic remission i

258 d with those of patients with spontaneous or interferon alfa-induced resolution of acute or chronic i

259 disease after nephrectomy and treatment with interferon alfa, interleukin-2, or surgical resection of

260 Interferon alfa is the only effective treatment for pati

261 Interferon alfa is widely used for metastatic renal-cell

262 lower dose combinations of interleukin-2 and interferon alfa may be as beneficial as higher dose regi

263 al resection (n = 8), rituximab (n = 2), and interferon alfa (n = 1).

264 26), respectively, when randomly assigned to interferon alfa (n = 97).

265 When interferon alfa-n/n3 and a lower dosage of ribavirin (60

266 omy and lymphadenectomy to observation or to interferon alfa-NL (Wellferon, Burroughs-Wellcome, Resea

267 linical response or combination therapy with interferon alfa or other novel agents, may be considered

268 g status, race, pretransplant treatment with interferon-alfa or hydroxyurea, and patient/donor ABO co

269 val (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005).

270 erapy and 86 patients treated with pegylated interferon alfa (Peg-IFN) and adefovir.

271 ir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in

272 acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significa

273 Pegylated interferon alfa (PEG-IFNalpha) is effective in only 25%-

274 patitis C virus (HCV) infection is pegylated interferon alfa (PEG-INF) and ribavirin, which can be di

275 ent of HCV remained stagnant, with pegylated interferon alfa (PegIFN) plus ribavirin (RBV; PegIFN/RBV

276 ts who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short du

277 ients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them

278 e, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML

279 chronic phase to receive either imatinib or interferon alfa plus cytarabine.

280 se CML were randomly assigned to imatinib or interferon alfa plus subcutaneous low-dose cytarabine (I

281 Interferon alfa prolongs life in comparison with convent

282 Interferon alfa remains the central treatment for chroni

283 efinition of response, and the management of interferon alfa responders remain controversial.

284 e on MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2

285 As compared with interferon alfa, temsirolimus improved overall survival

286 erapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines.

287 During the first 12 weeks of interferon alfa therapy, symptoms consistent with a diag

288 ant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patient

289 alfa and continued for the first 12 weeks of interferon alfa therapy.

290 untries who had relapsed after responding to interferon-alfa therapy were randomized to monotherapy (

291 g of temsirolimus weekly plus 6 million U of interferon alfa three times weekly.

292 taneous and mucous hyperpigmentations during interferon alfa treatment have been reported, but they a

293 Secondary hyperpigmentation during interferon alfa treatment occurs as an adverse event in

294 In contrast to interferon-alfa treatment, imatinib mesylate-treated CML

295 Interferon-alfa treatment-experienced patients (n = 42)

296 Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients

297 he study selection included studies in which interferon alfa was used for treatment of chronic hepati

298 gnificantly higher in the group treated with interferon alfa, whereas diarrhea was more frequent in t

299 fficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNalpha/Syn3), a replica

300 ravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcu